BIO — Bio-Rad Laboratories, Inc.

Is BIO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Medical Devices

Strong Oversold As of November 17, 2026

Bio-Rad Laboratories, Inc. (BIO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Devices) last closed at $358.19. The rating moved from Oversold to Strong Oversold on November 16, 2026.

See all oversold Healthcare stocks →

AI analysis

Bio‑Rad combines a diversified diagnostics and life‑science tools franchise with recurring reagent and service revenue that supports cash flow stability. Near‑term upside is tied to instrument order recovery, consumables growth and selective exposure to biopharma service channels; downside centers on capital spending cyclicality, reimbursement and execution risks. Market flows remain consolidated, offering a supportive backdrop for healthcare names while earnings cadence and product launches will be the principal catalysts for direction over the coming weeks.

Key factors

  • Diversified portfolio across clinical diagnostics and life‑science instruments with a steady consumables/ reagent attach rate that supports recurring revenue and margin stability
  • Large installed base of instruments drives recurring service, consumable and software revenue, improving visibility into cash flows
  • Exposure to biopharma services and specialty distribution channels which could capture incremental prescription and testing flows amid shifting treatment paradigms
  • Historically consistent free cash flow generation and manageable balance sheet that supports organic investment and selective M&A to expand specialty offerings
  • Product cycle and new product launches can drive periodic upside in instrument orders and higher-margin consumables
  • Market context shows defensive flows into healthcare names and selective support for growth-oriented healthcare equities, which can reduce downside volatility in near term

Risks

  • Cyclicality in capital equipment spending from academic, biotech and hospital customers that can cause order/timing volatility
  • Pricing and reimbursement pressure in diagnostics and clinical channels; regulatory changes or payer scrutiny could compress margins
  • Competition from larger diversified diagnostics and specialized life‑science vendors on instruments, consumables and service contracts
  • Supply‑chain disruptions or component shortages that delay instrument deliveries and service revenue recognition
  • Foreign-exchange exposure and geopolitical risks that may affect international revenue and margins
  • Execution risk on new product commercialization or any M&A integration
  • Potential slowdown in research funding or biopharma R&D budgets that reduces instrument and reagent demand

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for BIO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.